This phase 2 trial aims to test the effectiveness of a combined treatment with Brentuximabvedotin (Adcetris) in patients 60 years of age or more with Hodgkin lymphoma. The main outcome to be measured will be tumor response to the treatment and side effects. This trial is recruiting throughout the United States.
The details
Brentuximab vedotin is a treatment that binds to the lymphoma cell, leading to cancer cell death. This treatment is often used in relapsed Hodgkin lymphoma.
The current study will examine the use of brentuximab vedotin as a first-line therapy in patients over the age of 60. The main outcomes to be measured will include tumor response to the combination and treatment side effects.
Who are they looking for?
This trial will recruit 100 participants 60 years old or more. Patients must not have neurological disease or be currently treated with other drugs used in study. Participants who received chemotherapy, radiation therapy or biological therapy within 4 weeks prior to the start of this trial will not be included.
How will it work
Patients will be assigned to one of four groups. All the patients will receive brentuximab (1.8 mg/kg every 3 weeks by injection). Some patients will also receive bendamustine (70 mg/m2 by injection on days 1 and 2), dacarbazine (375 mg/m2 every 3 weeks by injection), or nivolumab (3 mg/kg every 3 weeks by injection). Treatment will continue until disease progression or unacceptable side effects.
The tumor response to the treatment will be determined following the last treatment. Side effects will be reported. Patients will be followed for an average of 2 years.
